Literature DB >> 33924959

Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Elisa Taiana1,2, Maria Eugenia Gallo Cantafio3, Vanessa Katia Favasuli1,2, Cecilia Bandini4,5, Giuseppe Viglietto3, Roberto Piva4,5, Antonino Neri1,2, Nicola Amodio3.   

Abstract

Multiple myeloma (MM) is a complex hematological malignancy characterized by abnormal proliferation of malignant plasma cells (PCs) within a permissive bone marrow microenvironment. The pathogenesis of MM is unequivocally linked to the acquisition of genomic instability (GI), which indicates the tendency of tumor cells to accumulate a wide repertoire of genetic alterations. Such alterations can even be detected at the premalignant stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) and, overall, contribute to the acquisition of the malignant traits underlying disease progression. The molecular basis of GI remains unclear, with replication stress and deregulation of DNA damage repair pathways representing the most documented mechanisms. The discovery that non-coding RNA molecules are deeply dysregulated in MM and can target pivotal components of GI pathways has introduced a further layer of complexity to the GI scenario in this disease. In this review, we will summarize available information on the molecular determinants of GI in MM, focusing on the role of non-coding RNAs as novel means to tackle GI for therapeutic intervention.

Entities:  

Keywords:  DNA damage response; DNA repair; base excision repair; genomic instability; homologous recombination; multiple myeloma

Year:  2021        PMID: 33924959     DOI: 10.3390/cancers13092127

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  98 in total

Review 1.  A review of trabectedin (ET-743): a unique mechanism of action.

Authors:  Maurizio D'Incalci; Carlos M Galmarini
Journal:  Mol Cancer Ther       Date:  2010-07-20       Impact factor: 6.261

Review 2.  Molecular mechanisms of long noncoding RNAs.

Authors:  Kevin C Wang; Howard Y Chang
Journal:  Mol Cell       Date:  2011-09-16       Impact factor: 17.970

3.  Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma.

Authors:  Elisa Taiana; Vanessa Favasuli; Domenica Ronchetti; Katia Todoerti; Francesca Pelizzoni; Martina Manzoni; Marzia Barbieri; Sonia Fabris; Ilaria Silvestris; Maria Eugenia Gallo Cantafio; Natalia Platonova; Valeria Zuccalà; Lorenza Maltese; Debora Soncini; Samantha Ruberti; Michele Cea; Raffaella Chiaramonte; Nicola Amodio; Pierfrancesco Tassone; Luca Agnelli; Antonino Neri
Journal:  Leukemia       Date:  2019-08-19       Impact factor: 11.528

Review 4.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.

Authors:  Michael R Lieber
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

5.  DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe.

Authors:  Amanda K Ashley; Meena Shrivastav; Jingyi Nie; Courtney Amerin; Kyle Troksa; Jason G Glanzer; Shengqin Liu; Stephen O Opiyo; Diana D Dimitrova; Phuong Le; Brock Sishc; Susan M Bailey; Greg G Oakley; Jac A Nickoloff
Journal:  DNA Repair (Amst)       Date:  2014-05-10

6.  DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.

Authors:  Mark R Velangi; Elizabeth C Matheson; Gareth J Morgan; Graham H Jackson; Penelope R Taylor; Andrew G Hall; Julie A E Irving
Journal:  Carcinogenesis       Date:  2004-05-13       Impact factor: 4.944

7.  Alternative 3'-end processing of long noncoding RNA initiates construction of nuclear paraspeckles.

Authors:  Takao Naganuma; Shinichi Nakagawa; Akie Tanigawa; Yasnory F Sasaki; Naoki Goshima; Tetsuro Hirose
Journal:  EMBO J       Date:  2012-09-07       Impact factor: 11.598

8.  Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Venkata Yellapantula; Marta Łuksza; David Hoyos; Kylee H Maclachlan; Benjamin T Diamond; Benjamin D Greenbaum; Gareth Morgan; Alexander Lesokhin; Elli Papaemmanuil; Ola Landgren
Journal:  Leukemia       Date:  2019-12-13       Impact factor: 11.528

9.  Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

Authors:  R Szalat; M K Samur; M Fulciniti; M Lopez; P Nanjappa; A Cleynen; K Wen; S Kumar; T Perini; A S Calkins; E Reznichenko; D Chauhan; Y-T Tai; M A Shammas; K C Anderson; J-P Fermand; B Arnulf; H Avet-Loiseau; J-B Lazaro; N C Munshi
Journal:  Leukemia       Date:  2017-06-07       Impact factor: 11.528

10.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.

Authors:  N Amodio; M T Di Martino; U Foresta; E Leone; M Lionetti; M Leotta; A M Gullà; M R Pitari; F Conforti; M Rossi; V Agosti; M Fulciniti; G Misso; F Morabito; M Ferrarini; A Neri; M Caraglia; N C Munshi; K C Anderson; P Tagliaferri; P Tassone
Journal:  Cell Death Dis       Date:  2012-11-29       Impact factor: 8.469

View more
  3 in total

Review 1.  Genome Instability in Multiple Myeloma: Facts and Factors.

Authors:  Anna Y Aksenova; Anna S Zhuk; Artem G Lada; Irina V Zotova; Elena I Stepchenkova; Ivan I Kostroma; Sergey V Gritsaev; Youri I Pavlov
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

Review 2.  The Landscape of lncRNAs in Multiple Myeloma: Implications in the "Hallmarks of Cancer", Clinical Perspectives and Therapeutic Opportunities.

Authors:  Ilaria Saltarella; Benedetta Apollonio; Aurelia Lamanuzzi; Vanessa Desantis; Maria Addolorata Mariggiò; Jean-François Desaphy; Angelo Vacca; Maria Antonia Frassanito
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

Review 3.  Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity.

Authors:  Carmine Rocca; Ernestina Marianna De Francesco; Teresa Pasqua; Maria Concetta Granieri; Anna De Bartolo; Maria Eugenia Gallo Cantafio; Maria Grazia Muoio; Massimo Gentile; Antonino Neri; Tommaso Angelone; Giuseppe Viglietto; Nicola Amodio
Journal:  Biomedicines       Date:  2022-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.